Population gate
Area (µm²)
Nuclei intensity & morphology
Nucleoli morphology
Nucleoli count
con A mean area and intensity
con A mean area
con A mean intensity
con A puncta
con A puncta count
Mitochondria morphology
Mitochondrial area

We used image set BBBC022v1 [Gustafsdottir et al., PLOS ONE, 2013], available from the Broad Bioimage Benchmark Collection [Ljosa et al., Nature Methods, 2012].

Metric Mean Median SD n
N children set5 7.41 3 11.9 3976
⏺︎ Control
7.02 5 7.97 1449
⏺︎ FAP
5.79 1 10.5 560
⏺︎ LOP
15 8 20.0 384
⏺︎ NFA
1.42 0 4.66 474
⏺︎ NIC
8.05 2.50 11.3 386
⏺︎ SBZ
11.0 6 14.9 276
⏺︎ VIT
7.73 2 13.8 447
Population 8

No version history available

Ungrouped Files

No ungrouped images

⏺︎

CTRL_20585_B13_s1.tif
CTRL_20585_B13_s2.tif
CTRL_20585_B13_s3.tif
CTRL_20585_B13_s4.tif
CTRL_20585_B13_s5.tif
CTRL_20585_B13_s6.tif
CTRL_20585_B13_s7.tif
CTRL_20585_B13_s8.tif
CTRL_20585_B13_s9.tif
CTRL_20585_B14_s1.tif
CTRL_20585_B14_s2.tif
CTRL_20585_B14_s3.tif
CTRL_20585_B14_s4.tif
CTRL_20585_B14_s5.tif
CTRL_20585_B14_s6.tif
CTRL_20585_B14_s7.tif
CTRL_20585_B14_s8.tif
CTRL_20585_B14_s9.tif
CTRL_20585_C11_s1.tif
CTRL_20585_C11_s3.tif
CTRL_20585_C11_s4.tif
CTRL_20585_C11_s7.tif
CTRL_20585_C11_s8.tif
CTRL_20585_C12_s2.tif
CTRL_20585_C12_s3.tif

⏺︎

TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s1.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s2.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s3.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s4.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s5.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s6.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s7.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s8.tif
TREATED_6-Furfurylaminopurine_4.65mM_20585_A04_s9.tif

⏺︎

TREATED_LOPERAMIDE_5.24mM_20585_A05_s1.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s2.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s3.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s4.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s5.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s6.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s7.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s8.tif
TREATED_LOPERAMIDE_5.24mM_20585_A05_s9.tif

⏺︎

TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s1.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s2.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s3.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s4.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s5.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s6.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s7.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s8.tif
TREATED_NIFLUMIC_ACID_8.86mM_20585_A01_s9.tif

⏺︎

TREATED_NICARDIPINE_5.21mM_20585_A03_s1.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s2.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s3.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s4.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s5.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s6.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s7.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s8.tif
TREATED_NICARDIPINE_5.21mM_20585_A03_s9.tif

⏺︎

TREATED_Suxibuzone_2.28mM_20585_A06_s1.tif
TREATED_Suxibuzone_2.28mM_20585_A06_s2.tif
TREATED_Suxibuzone_2.28mM_20585_A06_s3.tif
TREATED_Suxibuzone_2.28mM_20585_A06_s4.tif
TREATED_Suxibuzone_2.28mM_20585_A06_s5.tif

⏺︎

TREATED_Vitexin_2.31mM_20585_A02_s1.tif
TREATED_Vitexin_2.31mM_20585_A02_s2.tif
TREATED_Vitexin_2.31mM_20585_A02_s3.tif
TREATED_Vitexin_2.31mM_20585_A02_s4.tif
TREATED_Vitexin_2.31mM_20585_A02_s5.tif
TREATED_Vitexin_2.31mM_20585_A02_s6.tif
TREATED_Vitexin_2.31mM_20585_A02_s7.tif
TREATED_Vitexin_2.31mM_20585_A02_s8.tif
TREATED_Vitexin_2.31mM_20585_A02_s9.tif